Literature DB >> 3608231

Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity.

P L Meroni, E N Harris, A Brucato, A Tincani, W Barcellini, A Vismara, G Balestrieri, G R Hughes, C Zanussi.   

Abstract

In a series of 42 positive sera, anti-mitochondrial type M5 antibodies (AMA-M5) were found most frequently in patients with SLE (24) and SLE-like syndromes. Patients with AMA-M5 displayed a higher prevalence of thrombocytopenia, thrombosis, biological false positive seroreactions for syphilis, lupus-like anticoagulant activity and anti-cardiolipin antibodies in comparison with a group of 43 SLE AMA-M5 negative patients. The strong association between anti-phospholipid and AMA-M5 antibodies cannot be explained entirely by cross-reactivity between these two groups of antibodies, as indicated by absorption experiments and studies using affinity purified antibody preparations. However, cardiolipin liposomes were able to reduce partially the titres of AMA-M5 sera, suggesting that a small population of AMA-M5 antibodies exists that cross-reacts with cardiolipin. The existence of this population was further substantiated by our demonstration that an IgM monoclonal antibody, from a patient with Waldenström's macroglobulinaemia, displayed both anti-cardiolipin and AMA-M5 activity, and AMA-M5 activity was completely inhibited by cardiolipin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608231      PMCID: PMC1542609     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  A new pattern of non-organ- and non-species-specific anti-organelle antibody detected by immunofluorescence: the mitochondrial antibody number 5.

Authors:  M T Labro; M C Andrieu; M Weber; J C Homberg
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

3.  Phosphorylation and redox states in ischemic liver.

Authors:  G Gaja; M E Ferrero; R Piccoletti; A Bernelli-Zazzera
Journal:  Exp Mol Pathol       Date:  1973-10       Impact factor: 3.362

4.  New antibody in early syphilis.

Authors:  D J Wright; D Doniach; M H Lessof; J L Turk; A S Grimble; R D Catterall
Journal:  Lancet       Date:  1970-04-11       Impact factor: 79.321

5.  Further purification of the mitochondrial inner membrane autoantigen reacting with primary biliary cirrhosis sera.

Authors:  Y Ben-Yoseph; E Shapira; D Doniach
Journal:  Immunology       Date:  1974-02       Impact factor: 7.397

6.  A new antimitochondria antibody (anti-M6) in iproniazid-induced hepatitis.

Authors:  J C Homberg; N Stelly; I Andreis; N Abuaf; F Saadoun; J Andre
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Mitochondrial antibodies in chronic liver diseases and connective tissue disorders: further characterization of the autoantigens.

Authors:  F Meek; E L Khoury; D Doniach; H Baum
Journal:  Clin Exp Immunol       Date:  1980-07       Impact factor: 4.330

9.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

10.  Inhibition of a nutrient-dependent pinocytosis in Dictyostelium discoideum by the amino acid analogue hadacidin.

Authors:  E F Rossomando; E G Jahngen; B Varnum; D R Soll
Journal:  J Cell Biol       Date:  1981-10       Impact factor: 10.539

View more
  15 in total

1.  High frequency of antiphospholipid antibodies in primary biliary cirrhosis.

Authors:  Amani Mankaï; Wiem Manoubi; Mariam Ghozzi; Sarra Melayah; Wahiba Sakly; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  Histopathological findings in a case of systemic lupus erythematosus-associated anti-phospholipid syndrome.

Authors:  P L Meroni; R Rivolta; P Ghidoni
Journal:  Clin Rheumatol       Date:  1991-06       Impact factor: 2.980

3.  Antimitochondrial antibodies in the antiphospholipid syndrome.

Authors:  N Abuaf; S Laperche; R Carsique; O Meyer; A Deschamps; B Rajoely; C Johanet; J C Homberg
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-beta2-glycoprotein I antibodies.

Authors:  L La Rosa; G Covini; C Galperin; L Catelli; N Del Papa; G Reina; A Morabito; G Balestrieri; A Tincani; M E Gershwin; P L Meroni
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

5.  Antiphospholipid antibodies, lupus-like disease and the "primary" antiphospholipid syndrome.

Authors:  R A Asherson; M A Khanashta; G R Hughes
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

6.  False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion.

Authors:  S Cowchock; J Fort; S Munoz; R Norberg; W Maddrey
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

7.  'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?

Authors:  P Muratori; L Muratori; M E Gershwin; A J Czaja; G Pappas; S MacCariello; A Granito; F Cassani; P Loria; M Lenzi; F B Bianchi
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

8.  Patterns of gastrin secretion in patients with nonfunctioning pituitary adenomas.

Authors:  L Persani; P Beck-Peccoz; M Quatrini; M Bassetti; B Travella; P Bianchi; G Faglia
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

9.  Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases.

Authors:  N Zurgil; R Bakimer; H M Moutsopoulos; A G Tzioufas; P Youinou; D A Isenberg; M Scheinberg; T Kveder; B Rozman; C Luderschmidt
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

10.  Sera from patients with systemic lupus erythematosus demonstrate enhanced IgG binding to endothelial cells pretreated with tumour necrosis factor alpha.

Authors:  N P Quadros; P J Roberts-Thomson; A S Gallus
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.